The
The ALPHA3 clinical study will evaluate an investigational CAR T-cell product called cemacabtagene ansegedleucel (or “cema-cel,” pronounced “SEM-a-sell”) in patients with diffuse large B-cell lymphoma (DLBCL) after they have completed their initial chemotherapy (known as first-line treatment). “Investigational” means that it has not been approved by regulatory agencies at this time.
The ALPHA3 clinical study uses an investigational diagnostic blood test to determine if patients with DLBCL and similar types of lymphoma are found to have what is known as minimal residual disease (MRD). Research shows that patients who are MRD negative (MRD-) are unlikely to have their cancer return1. However, patients who test MRD+ are considered to be at high risk of their cancer coming back (also called recurrence) and may be eligible to proceed to the next step in the clinical study.
The ALPHA3 Patient Journey
What Are the Potential Benefits?
Knowing your MRD status – whether positive or negative – may help you and your doctor better understand the likelihood of your cancer returning and help you plan for your future. If you are MRD-, this may provide peace of mind that your cancer is statistically unlikely to return.1 On the other hand, knowing if you are MRD+ may allow you and your care team to take steps to try and lessen its chances of coming back, such as deciding to participate in the next step of the ALPHA3 clinical study. An empowered, proactive approach to your cancer is here, and you may be eligible to take part.
What Is Being Tested?
The main goals of this clinical study are to predict who is at high risk of their cancer returning, and to explore whether one-time treatment with an investigational CAR T-cell product (cema-cel) may stop your cancer from coming back. Read our FAQ to learn more about this screening, treatment, and study, and what to expect as a participant.
Clinical Studies Make A Difference
The information that doctors and researchers learn from the ALPHA3 clinical study may help improve what they know about treatments for adult patients with DLBCL and similar types of lymphoma. When you participate in a clinical study, you provide valuable information that could eventually lead to a better treatment and – with the right breakthrough – to better outcomes.
Participate in Innovation
Help Others
Shape the Future
Still Have Questions?
Contact us to learn more.